

PCT

WORLD INTELLEC
Li

INTERNATIONAL APPLICATION PUBLISH



WO 9603112A1

(51) International Patent Classification 6:
A61K 9/00, 9/20, 47/32, 47/42

(43) International Publication Date: 8 February 1996 (08.02.96)

(21) International Application Number: PCT/GB95/01330

(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7
Eldon Street, London EC2M 7LH (GB).

(22) International Filing Date: 7 June 1995 (07.06.95)

(81) Designated States: JP, US, European patent (AT, BE, CH, DE,
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(30) Priority Data:
9414684.2 21 July 1994 (21.07.94) GB
9415405.1 25 July 1994 (25.07.94) GB
9502246.3 6 February 1995 (06.02.95) GB
9503357.7 21 February 1995 (21.02.95) GB

Published
With international search report.

(60) Parent Application or Grant

(63) Related by Continuation

US 07/988,919 (CIP)
Filed on 4 May 1993 (04.05.93)

(71) Applicant (for all designated States except US): SYNGENIX
LIMITED [GB/GB]; Mount Pleasant House, 2 Mount Pleasant,
Huntingdon Road, Cambridge CB3 0BL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FILLER, Aaron, Gershon
[GB/GB]; 31 Copse Hill, Wimbledon, London SW20 0NE
(GB). LEVER, Andrew, Michael, Lindsay [GB/GB]; 1
Maner's Way, Cambridge CB1 4SL (GB).

(54) Title: COMPOSITIONS COMPRISING A TISSUE GLUE AND THERAPEUTIC AGENTS

(57) Abstract

Especially for local radiotherapy, a therapeutic agent is applied with a tissue glue.

= FP 0804153
US 10/089,663

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech. Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Compositions comprising a tissue glue and therapeutic agents

Cross-Reference to Related Applications

This is a continuation-in-part of US Application
5 Serial No 07/988,919, filed May 4, 1993.

Field of the Invention

This invention is in the field of medical therapeutics and concerns novel means of delivering therapeutic agents. In particular, this concerns percutaneous or surgical 10 application of therapeutic agents which are intended to remain at or near the location at which they are placed by the treating physician or surgeon.

Background of the Invention

There are a number of problems in medicine for which 15 therapy requires direct physical placement of a treating agent. However, the means for achieving this end are extremely limited and this end has seemed to be extraordinarily difficult to achieve.

It is often possible to deliver a drug to a specific 20 location, such as by the injection of local anaesthetic near a nerve which must be numbed. However, most small molecules will diffuse away from their injection site, or otherwise be removed and dispersed by the actions of the bloodstream, lymphatics and other movements of interstitial 25 fluids. In a number of situations, it is advantageous for the therapeutic agent to remain at the desired location for a much greater length of time.

It is sometimes possible to place a bead, capsule or 30 seed with an agent at a given location, but it is very difficult to apply such localised therapy over a surface rather than at a single point. Ideally there should be a rapid and effective means for coating certain surfaces in the human body with therapeutic agents.

One such problem, well known to surgeons who 35 specialise in the treatment of brain cancer (e.g. gliomas), arises because tumour cells infiltrate into the otherwise normal brain surrounding a gross tumour. The gross bulk of

tumour is removed surgically by craniotomy, however the margins of apparently normal brain always contain sufficient numbers of tumour cells as to make local recurrence of the tumour a virtual certainty. These 5 tumours do not metastasise, so local recurrence is generally the only type of recurrence to be expected.

To treat the small number of remaining cancer cells, chemotherapy can be given. However, even very toxic agents which cause severe toxic side-effects throughout the body 10 have only a very slight slowing effect on tumour cell growth of gliomas. Radiation therapy may be given but, in young children, the radiation causes grievous harm to the surrounding brain and, in adults as well, there is risk of 15 severe scarring from the radiation which can cause swelling and mass effects in large regions of the brain. Although radiation clearly slows the growth of the tumour, it is virtually impossible to deliver enough radiation to slow the tumour substantially without causing unacceptable damage to the brain. Results for treatment of brain cancer 20 remain dismal, and life expectancy after diagnosis is measured in months with or without surgery.

One significant recent advance comes from improved methods of applying 'brachytherapy'. In some brachytherapy approaches, multiple hollow latex catheters with 25 radioactive material in their tips are inserted into the brain, generally with computer and image-guided stereotactic methodology or by use of any one of a number of computer and image-guided spatial position wands. These catheters cause a risk of infection spreading along the 30 catheter and do not provide a uniform field of radiation and are not well suited for treating the surface of the tumour resection bed in the brain.

In one improvement which is currently the best state of the art, the radioactive material, commonly an isotope 35 of iodine, is enclosed in small stainless steel or titanium 'seeds' which are 0.8 mm x 4.5 mm in size. Immediately after the surgeon resects the tumour, and before any

surgical closure is commenced, the surgeon uses a tissue adhesive such as a cyanoacrylate-based glue to attach the seeds to the brain surface along the plane of tumour resection. A tumour which was 4 cm in diameter has a surface area of e.g. 30-40 cm² of resection bed and may require some eighty or ninety individual seeds to be glued in place, one by one, in a grid pattern with as regular a spacing as possible. Each seed has a radioactive source which treats a surrounding sphere with low level, low penetration energy for use over a long period of time until the radiation decays away over, e.g. 3-4 months. The seeds are left in place.

The problem with this current method is that the painstaking process of gluing on the seeds requires as much as an hour during which time the full operating room team (surgeon, assistant surgeon, radiation therapy treatment planner, radiation therapy technician, anaesthesiologist, scrub nurse, circulating nurse) are all required to be present and are all subject to unshielded radiation exposure.

An alternative type of glue for surgical use is termed a 'tissue glue'. This is a natural biological material that takes advantage of natural components of the human clotting system. The clotting proteins and cofactors are either extracted from donor blood, or extracted from the patient's own blood prior to surgery, or, in many cases now, extracted from the patient's own blood during the surgery itself. Typically, the glue is maintained in two components, one with fibrin protein solution and the other with e.g. the calcium solution which helps activate the clotting cascade. The two components are loaded into two separate syringes and the needle tips from the two syringes are bent to run parallel to each other so that the two tips are closely apposed. The surgeon uses a double syringe apparatus to apply the two fluids to the surface of interest simultaneously. As the two fluids emerge from the needle tips onto the tissue surface they mix and congeal.

This material is used for plugging leaks in the dura membranes around the brain in order to prevent leakage of spinal fluid as well as for a wide variety of other surgical applications including the assistance of wound 5 closure and haemostasis. Tissue glues have also been proposed as means of achieving slow controlled release of various growth factors and antibiotics.

It is not possible to suspend the seeds in either a liquid cyanoacrylate glue or in either component of a 10 tissue glue as described above, because they would sink out of solution. It would be possible to include a variety of radioactive metal cations in chelate molecules and then dissolve these molecules in a tissue glue component; however, even for very large proteins, the tissue glue 15 allows migration of the molecules through its interstices. Thus from the point of view of most molecules, the glue is not a glue at all, but only a matrix through which they can diffuse along with the tissue water in which they are dissolved.

20 Summary of the Invention

In a broad aspect of the invention, a ferrite or other radiotherapeutic agent, in particulate form, is suspended in a tissue glue, suitably in the pre-mix. If a colloidal solution of, say, β -emitting ferrite is prepared in a 25 tissue glue, this can be applied after surgical resection of a tumour, particularly near an eloquent area of the brain, where a thin shell of tumour may remain, minimising exposure to the surgeon and operating staff. The particles are biodegradable, and so will be resorbed over weeks. A 30 cell adhesion moiety-coupled radionuclide may be used, if the agent is not physically held in the matrix.

Further aspects of the invention are indicated below and are also defined by the claims. Apparatus of the invention is illustrated in the drawings, and comprises any 35 combination of the means illustrated for achieving the given purpose.

Description of the Invention

The radiotherapeutic agent may be any of a variety of nuclides, depending on the energy, penetration or half-life that is desired. Appropriate choice of such criteria is 5 within the skill of those knowledgeable in the art. It is preferably a ferrite, e.g. a β -emitting ferrite, and preferably comprises a chelate.

Suitable tissue glues are also known. This component may be, for example, based on a clottable protein such as 10 fibrinogen. For example, a glue such as Tisseel (available from Immuno Danmark A/S of Copenhagen) may be used. Tissue glues, including fibrin and cyanoacrylates, are also described by, for example, Kottai *et al.*, Ann. Otol. Rhinol. Laryngol. (1983 Jan-Feb) 92(1 Pt 1):29-32; Ronis *et al.*, 15 Laryngoscope (1984 Feb) 94(2 Pt 1):210-3; Barnstable, Nature (1986 Jun 19-25) 321 (6072):731-2; Toriumi *et al.*, Otolaryngol. Clin. North Am. (1994 Feb) 27(1):203-9; and 20 Schlag *et al.*, in Fibrin Sealant in Operative Medicine Vo. 1, G. Schlag. 11. Redl (eds), Springer-Verlag Berlin-Heidelberg (1986) 27-38.

The term "tissue glue" is used herein in its broad sense, i.e. as any tissue-compatible matrix within which the active component is retained, suitable for topical or other application to the locus of treatment. It may 25 therefore be a gel-like substance comprising pores within which the agent is held. It will often be proteinaceous, and usually it will be biodegradable.

According to one aspect of this invention, it has been appreciated that larger particles can readily be 30 immobilised in a variety of gels such as the tissue glue. Further, these particles are made in such a way that they can be fully and stably dissolved in water or in e.g. the calcium fluid component of the tissue glue, yet these 35 particles are small enough to be sterilised by filtration methods along with the solution in which they are dissolved. The particles can be manufactured in such a way as to incorporate a wide variety of different metal

cations, including their radioactive isotopes (to include emitters of β -particles, α -particles, γ -rays, or X-rays from K-capture decay) in the ferrite crystal matrix at their core. The nuclides are very stably incorporated into the ceramic type core of 10-200 nanometers in diameter and the core is coated in any one of a variety of macromolecules such as dextran.

5 These particles can be made radioactive in several different ways. It is only necessary to dissolve radioactive isotopes of certain metals as soluble metal chlorides in the initial metal chloride solution prior to the ferrite precipitation step disclosed in WO-A-9305815 and US Application Serial No. 08/211,041, filed March 16, 1994, the content of which is incorporated by reference.

10 The isotope palladium-103 ($t^1/2 = 17$ days, EC) is extremely useful for brachytherapy with permanent implants because of its useful half-life which allows treatment of a cancer as various cells in the tumour pass into the radiosensitive cell division process over the course of 15 days and weeks. The X-rays produced by its electron capture decay have low energy (half-value thickness in water of 1.6 centimetres) and hence it is possible to have exceedingly precise control over the area treated, as for 20 example in the post-excision area where invisibly small 25 amounts of tumour may have invaded surrounding normal tissue to a depth of a few millimetres. It is also the case, as is disclosed in WO-A-9211846 and US Application 30 Serial No. 08/087,781, filed July 7, 1993 (the content of which is incorporated by reference) that palladium is very readily incorporated into spinel ferrites in stable fashion.

35 Two readily available methods exist for the production of ^{103}Pd . The first is by the use of low energy neutrons from a production reactor to irradiate the ^{102}Pd stable isotope. It should be noted that this method has the disadvantage that ^{102}Pd is only one of five different stable isotopes of palladium (see Table 1) and makes up only 1% of

naturally-occurring palladium. For reasons discussed below, it is necessary to extract the 102 isotope prior to irradiation because of the undesirable qualities of the other resulting radioisotopes if the full mixture of stable palladium isotopes is irradiated (see Table 2). The second method for production of ^{103}Pd is to use a high energy cyclotron capable of causing reactions with protons (conventional cyclotrons use deuterons and alpha particles which have greater mass/charge). Such an instrument can be used to irradiate rhodium which occurs naturally as only a single isotope, ^{103}Rh , so that all conversions are to ^{103}Pd which is then separated chemically from the rhodium in carrier free form.

Another medically useful nuclide for delivery with ferrite or other particles is yttrium-90 ($t^{\frac{1}{2}}=64$ hours, β^- , 2.283 MeV). This is readily produced from low energy neutron irradiation of ^{89}Y since 100% of natural yttrium occurs in this form. The pure beta emission and half-life are suitable for such tasks as radiation synovectomy and treatment of other very thin layers of disordered tissue. The provision of ^{90}Y in an appropriate liquid carrier has been a problem for many years since, for intra-articular use, small molecule carriers and colloids tend to leak out of the joint, while large particles do not distribute properly because they do not remain in solution. It has been suggested previously in WO-A-9211846 (see above) that various lanthanides can be incorporated into garnet ferrite-type crystals. For the inclusion of yttrium, a second period Group IIIB element, it has been appreciated that the stability and efficiency of incorporation can be improved by forcing the yttrium into a modified spinel crystal.

The prototype mineral spinel (MgAl_2O_4) is based on a close-packed, face-centred, cubic crystal of oxygen atoms with metal ions placed at interstitial spaces in the crystal. There are A spaces which accommodate ions of 0.3 to 0.6 angstroms (8 sites/subunit) and B spaces which

accommodate ions of 0.6 to 1.0 angstroms (16 sites/subunit). In natural spinel, the divalent magnesium ions are in the A spaces and the trivalent aluminum ions are in the B spaces. Magnetite is an 'inverse spinel' because the crystal subunit of 32 O²⁻ anions has trivalent Fe³⁺ in the 8 A-sites, with 8 B-sites occupied by divalent Fe²⁺ and 8 B-sites occupied by trivalent Fe³⁺.

When Zn²⁺ cations are substituted for Fe²⁺ cations in the initial mixture, they tend to enter the A-sites because they are slightly smaller than the Fe²⁺ cations. This forces the crystal into a 'spinel' configuration. However, as the concentration of Zn²⁺ approaches 50% of the divalent cation, the crystal has steric problems because the Zn²⁺ cations are still actually a bit too large for these A-sites. Above 50% Zn²⁺, the crystal produced is again an inverse spinel and these effects are well studied because of their impact upon the magnetisation of bulk ferrites. An entirely unanticipated aspect of this system has been discovered, i.e. that under these conditions of flux in the crystal structure near a 50/50 mix of Zn²⁺ and Fe²⁺, the large Y³⁺ cations are more readily accommodated in the crystal and a more stable mixed ferrite results. This may also reflect retention of partial inverse spinel structure with smaller Zn²⁺ cations in enough of the B-sites to allow for additional space to accommodate Y³⁺ in the B-matrix as well.

An alternative manoeuvre is to use Li¹⁺ cations to balance the stoichiometry when replacing Fe²⁺ cations with Y³⁺ cations. The Li and Y are added in equal amounts as the Fe²⁺ is reduced. However, the Fe^{3+}/Y³⁺ : Fe^{2+}/Zn²⁺ system produces a stable yttrium-carrying ferrite with medically useful qualities.}}

The incorporation of yttrium in particles for radiation synovectomy also makes possible a solution to one of the principal problems now limiting the use of this procedure. A needle is used to inject the material into the joint, but when the needle is withdrawn some of the

radioactive material becomes subject to leakage out of the joint. To minimize this problem, patients are now required to remain motionless in bed in hospital for several days.

The incorporation of the radioactive yttrium into ferrites makes possible several methods of limiting the leakage and subsequent spread of radioactivity. Firstly, the knee can be wrapped in a magnetic coil which will prevent any leaked radioactive ferrites from spreading out of the area. More simply, however, tissue glues can be used to help seal the joint capsule. Because the radioactivity is incorporated in a substance which does not diffuse through tissue glue, the application of tissue glue to the injection site will prevent leakage. The half-life of the ^{90}Y is sufficiently short that most of the radioactivity will have decayed before the tissue glue will have broken down. In this aspect, the invention provides a system which inhibits unwanted spread of synovectomy agent.

In a further modification, the ^{90}Y -ferrites may be fully incorporated into the tissue glue at the time of injection into the joint via a double-barrelled, double-needle syringe. The, say, fibrin glue is allowed to set within the involved joint, but its injection is accompanied by agents which help promote fibrinolysis, such as tissue plasminogen activator, or it is applied in a specially modified tissue glue preparation which is compounded to hold a lower concentration of fibrinogen than is usually used. In this fashion it can be assured that the ferrite-containing gel will dissolve over 2-4 days during which time much of the activity of the ^{90}Y will be retained. During the breakdown process, macrophages are known to be actively attracted into the matrix and will ingest radioactive particles as well. This will thus serve as a means of both reducing leakage from the joint and effectively loading macrophages with radioactive ferrites so that when they subsequently distribute to the synovium they will be highly active.

Most effectively, the technique will involve a three-stage injection into the knee from a four-barrelled syringe. One barrel contains low fibrinogen glue component mixed with radioactive ferrites, another barrel contains 5 the calcium solution, a third barrel contains ferrite-free fibrinogen solution, and a fourth contains radioactive ferrites in a suitable buffered aqueous medium with an x-ray contrast agent such as iohexal. After introduction of the double needle into the joint, the injection is 10 commenced with radioactive ferrites in aqueous medium. Next the needle is partly withdrawn (under fluoroscopic guidance) to near the exit from the joint capsule, and here an injection is done to mix radioactive low fibrin glue component with the calcium solution. Finally, the needle 15 is withdrawn to just outside the joint and non-radioactive tissue glue is then administered to fully seal the joint capsule.

It has further now been appreciated that alternative means of incorporating radioactivity in the ferrites will 20 sometimes be useful. One such alternative method is to include in the crystal matrix an element or isotope which is the 'parent' of the desired isotope. The entire formed particle, in aqueous solution, is then bombarded with neutrons in a reactor or with protons, deuterons, or alpha 25 particles from a cyclotron beam or nucleons from a linear accelerator in order to render the parent nuclide into the desired daughter isotope. This method has the disadvantage of causing some of the carrier iron atoms and the carbon, hydrogen, and oxygen atoms in a dextran coat to be 30 converted to possibly undesirable isotopes as well. However, the dextran atoms are present in far lower concentration than the atoms in the particle, so the situation of the ferrite alone can reasonably be considered as the greatly predominating source of post-irradiation 35 nuclides.

There are however a variety of nuclear reactions involving iron isotopes which would typically be considered

as non-productive or useless in that the resulting nuclides are themselves a mixture of stable isotopes of no medical use. It has now been appreciated, however, that in the setting of this type of ferrite carrier, the objective is 5 properly to change carrier atoms only into different stable carrier atoms, while the therapeutic or diagnostic daughter nuclide included in the matrix results from a selectively introduced parent isotope incorporated chemically prior to the irradiation.

10 Such primarily stable shifting takes place in the course of low energy neutron bombardment in a reactor. Naturally-occurring stable iron is 92% ^{56}Fe , 6% ^{54}Fe , 2% ^{57}Fe and 0.3% ^{58}Fe . After low energy neutron bombardment, the majority of atoms (^{56}Fe) will be changed to ^{57}Fe which is 15 just a different stable isotope and the existing ^{57}Fe converts to stable ^{58}Fe . In this case however, the ^{54}Fe becomes ^{55}Fe with 2.7 yr half-life and EC capture decay, and the small amount of natural ^{58}Fe becomes ^{59}Fe with 45 day half-life and β and gamma decay. As shown in the attached 20 Table 3, the oxygen in the crystal as well as the carbon and oxygen in the dextran are converted substantially to stable isotopes by this reaction (n, γ). If such particles are held in storage for e.g. 10 half-lives of the ^{59}Fe , the very small starting amount will be reduced to a negligible 25 contribution, and the resulting particles will remain as a long half-life EC capture emitter. Such a material could be useful in the fabrication of temporary implants for brachytherapy where the implant is cast in the form of seeds, catheters, or reusable, pumpable liquid for 30 catheter-based, temporary brachytherapy.

To use low energy neutron bombardment (n, γ) for non-productive change, it would be necessary to prepare the ferrites from ^{56}Fe -enriched iron to minimize undesired radioactive products. However, any ^{102}Pd included in such 35 a ^{56}Fe -enriched ferrite would be converted to useful ^{103}Pd ($t^{1/2}=17\text{ days}$, EC). As shown in Table 2, it is important that virtually no ^{106}Pd be included in the starting particle for

this treatment since it would be converted into a very long half-life, low energy beta-emitter (^{107}Pd , 6.5×10^6 y, β^- , .033 MeV, decaying to stable ^{107}Ag). However, for the preparation of permanent implants, this would be a desirable effect, and natural, mixed isotope palladium could be used as a starting material. The small amount of ^{103}Pd produced would decay to negligible amounts after ten half-lives (170 days), after which the material could be treated as an effectively permanent source of low energy beta particles. In yet another aspect, because of the extremely low energy of these beta particles, the use of a plastic or silastic capsule or a titanium capsule around a seed cast to include such ferrites, or a thin, e.g. 1 mm, layer of ferrite-free tissue glue would provide nearly complete shielding of the beta emissions. In this way, the natural palladium ferrite could still be used as a permanent implant emitting effectively only the desirable X-rays from electron capture decay of ^{103}Pd . The ^{109}Pd (13h, β^- , 1 MeV) produced from natural ^{103}Pd would still make it necessary to hold the particles for at least ten of these half-lives (130 hours) to reduce this beta output if it was desired to use only EC X-rays. However, in many therapeutic situations, inclusion of a 1 MeV beta particle would be useful along with the EC X-rays.

Fast neutron bombardment of ^{56}Fe -enriched ferrites is another feasible means of producing useful medical isotopes via the (n,p) reaction. The various nuclides produced from the dextran-coated ferrite carrier are all very short-lived (see Table 3).

Use of a high energy cyclotron to bombard ^{56}Fe -enriched ferrites with protons results in ^{56}Co which is a relatively long half-life (77 days) positron-emitter. In both these cases, the advantage is in the ability to incorporate the radioactivity after the chemical preparation, clean up, and concentration steps have been completed. This avoids exposure to those involved in preparing the material and is particularly helpful in preparing positron-emitting

ferrites since it is extremely difficult and awkward to shield production workers from positron annihilation photons due to their high energy.

In yet another aspect, the bombardment of ^{56}Fe -enriched dextran-coated ferrites with alpha particles would produce ^{58}Ni ($\alpha, 2n$) which is stable but would have the advantageous effect of converting oxygen atoms in the ferrite crystal as well as in the dextran into the short half-life (110 min) positron-emitter ^{18}F (α, pn) which has a wide variety of medical uses; however, the side-reaction of (α, pn) production of ^{58}Co ($70\text{d}, \beta^+$) limits the value of this production method. Treatment of dissolved dextran by alpha bombardment prior to the precipitation reaction would cause the inclusion of ^{18}F in both the dextran coat and in the interior of the crystal.

A completely different way of adding radioactivity after manufacture of the ferrites or of any other useful particle of the desired size range is to conjugate chelating groups such as EDTA, NTA or DTPA to the dextran coat of the ferrite or surface group of any other particle. In this fashion, all preparation steps are done with non-radioactive materials. Finally, when the material is to be shipped for use, or even at the site of use, the chelate-conjugated particles are exposed to dissolved radioactive metals or other chelatable elements. The elements need only have higher binding affinity to the chelate than e.g. sodium used to fill the chelate prior to radioactive uptake.

After exposure of an excess of the particles to the radioactive material, it is optionally possible to use centrifugal ultrafilters or simply passage through Sephadex columns to separate the hot particle fraction from any unbound radioactive elements.

It should also be noted that the considerations discussed above concerning palladium isotopes also apply in this alternative situation in which a reactor is used to irradiate natural mixed palladium before preparation of the

ferrites in which such resulting palladium is dissolved and used to load chelator molecules conjugated to the dextran or other coat of the ferrite and additionally these considerations apply where the post-irradiation palladium 5 is used to make radioactive Fe-Pd ferrites by precipitation from dissolved irradiated palladium chloride.

It should additionally be noted that these considerations are not restricted to the element palladium but can readily be worked out as they apply to a wide 10 variety of medically useful nuclides when prepared for delivery in a ferrite-based particle.

Choice of the coating type and e.g. the size of dextran molecule to be used controls the final diameter of the particle. A 5,000 MW dextran coating will yield a 15 particle more likely to migrate in a loose gel which would be preferable for drug delivery, while a 100,000 MW dextran coat would tend to produce a particle which resides very stably in the matrix for e.g. radiotherapeutic applications. Final particles can be converted to larger 20 conglomerates by use of various conjugation reactions to create linkages between dextran molecules of multiple particles.

WO-A-9305815 and US Application Serial No. 08/211,041 disclose that the particle preparation can be cleansed of 25 any unincorporated or easily soluble cations through treatment with a chelation buffer. The buffer may comprise EDTA (ethylenediaminetetraacetic acid), DTPA (diethylenetriaminepentaacetic acid), NTA (nitrolotriacetic acid) or various other metal cation chelating agent either 30 with or without e.g. meglumine as a counter-ion. These chelation buffers act at least in part to dissolve metal hydroxide polymers without dissolving the magnetite or other mixed metal crystal. The dissolved, chelated ions which were not properly incorporated in the particles at 35 the time of the initial precipitation reaction are then easily separated from the particles. Originally, it had

been appreciated that this manoeuvre greatly improved the simplicity of manufacture of such ferrites.

It has now been appreciated that it is important to be able to remove any radioactive nuclides which are not stably incorporated in the particles when a brachytherapy product for therapeutic use is to be made from the resulting preparation. Application of tissue glue-borne nuclides relies on a very high proportion of all the radioactive nuclide migrating stably with the particle fraction during synthesis, since only the particle-bound fraction will be held stably by the matrix in vivo. The chelation buffer step was originally described in WO-A-9305815 and US Application Serial No. 08/211,041, as a means of improving the behaviour of particle solutions during filter purifications. It has now been found that this method results in a unique solution which provides an entirely novel mechanism for stably holding a variety of radionuclides stably in a matrix.

It should be appreciated that this innovation has uses not limited to tissue glues but also provides a convenient means for incorporating radionuclides into a wide variety of carriers of various types and useful for various purposes. These uses all have in common the need to hold a nuclide in place so that it is not allowed to move or diffuse or dissolve freely through the medium or carrier into which it has been introduced.

Any particle can contain a range of nuclide concentrations ranging from one atom per crystal, up to e.g. 100,000 or more atoms per crystal. This choice allows both for storage of the particles over the long term and for a wider choice of possible isotopes to be used depending upon the therapeutic task to hand. Groups of particles can also be conjugated together with periodation reactions or glutaraldehyde reactions in order to make them larger in the aggregate so that they achieve greater stability in looser gel matrices.

It should also be appreciated that this means of particle application is not restricted to tissue glue alone, but also applies to various other collagen matrices or other matrix or gel-forming substances tolerable for 5 biological use or foams or gelfoam substances as well as with a wide variety of other adhesive materials which can be used to hold particles and keep them at a chosen proximity to a particular target.

When fibrin-based tissue glue is used as the matrix 10 for immobilizing the particles of whatever type, the function of the invention will be greatly affected by the stability or rate of breakdown of the tissue glue matrix. Fibrin tissue glue is subject to breakdown from the action 15 of natural fibrinolytic proteins. The amounts and concentrations of these fibrinolytic proteins vary from tissue to tissue within the body. On average, a tissue glue layer in the human body would be expected to lose the greater part of its physical integrity within a period of about 10 days from application. In many cases this is 20 desirable, however in other cases it may be desirable to either extend or shorten the period of stability of such a gel. In the case of fibrin glues, there is a variety of 25 proteins and other agents well known to affect the natural metabolism of fibrin clots. These agents have been used for a variety of purposes but have not been considered as a means of manipulating the drug delivery properties of gels or as a means of controlling radiotherapy or gene 30 therapy.

One such agent is amicar (ϵ -aminocaproic acid). A 35 typical use is to slow the breakdown of clots which form on ruptured cerebral aneurisms and so to inhibit their risk of repeat haemorrhage. If amicar or similarly acting agents such as aproteinin or various proteinase inhibitors are incorporated in the gel matrix, either simply by mixing them into the initial solution or by adhering or 35 conjugating them to particulates intended to be included in the matrix, then these will slow the breakdown of the gel.

Alternatively, the inclusion of agents such as tissue plasminogen activator or streptokinase will speed the breakdown of the gel.

Prolongation or shortening the stability period of 5 gels has not previously been considered in relation to the use of tissue glues for drug delivery. This is because all previous descriptions of the use of tissue glue for drug delivery have involved drugs which diffuse out of the gel matrix fairly rapidly so that the length of time of 10 survival of the gel has little impact on the rate of delivery. However, in the current invention, many of the aspects of the drug delivery mechanism are closely dependent upon the rate of tissue glue breakdown.

In one aspect, a locally active protein which would 15 benefit from slow release, such as bone matrix protein, is conjugated to a particulate such as the dextran-coated ferrite. Many such proteins will retain their physiologic activity even though they are conjugated to a particle. The clinical problem is to provide slow release of the 20 protein from the gel. By immobilizing the protein/particle conjugate in the gel, the physiologic activity is delayed until the matrix is physically degraded. Here the particle acts as an anchor and the breakdown of the gel releases the anchor.

In another aspect where tissue glue is used to hold a 25 ¹⁰³Pd ferrite for brachytherapy, the half-life of the nuclide requires a relatively long period of stability of the gel in order to minimize spread from the site of application prior to the passage of three to five 30 half-lives. In tissues such as prostate with high concentrations of fibrinolytic proteins this a particular concern. Although a variety of longer-lasting synthetic and semi-synthetic gels can be used, the addition of an anti-fibrinolytic allows the use of fibrin tissue glue.

35 Yet another application is in the treatment of arterio-venous malformations in the brain. Currently these are treated non-surgically either by using intravascular

catheters to fill the vessels with an occluding matrix or by external beam therapy. In this invention, a tissue glue may be injected with radioactive ferrites (¹⁰³Pd or ⁹⁰Y). This would allow for simultaneous embolization and 5 radiation sclerosis of the AVM vascular walls. Prolonging the life of the tissue glue would help assure focal delivery as well as prolonging the life of the embolic vessel blockage. If the interventional radiologist found that too much vessel had been blocked, then fibrinolytics 10 could be applied to rapidly dissolve the gel and allow the radiation to diffuse through the body where it would be present in extremely low concentration because of the large volume of distribution relative to the amount of radioactive agent involved. The ferrites could also be 15 collected from the blood stream by a magnetic filter.

In order to localise therapeutic agents, various means involve tissue glue. One is based on physically conjugating a variety of carrier proteins directly onto the fibrin in the tissue glue. The conjugation can be carried 20 out through antibodies to the fibrin or through the use of periodate conjugation. The carrier proteins and dextran molecules incorporate chelate molecules in a variety of arrangements all well known to those expert in the art of therapeutic metal ion delivery. Additionally, this 25 includes non-metal therapeutic radionuclides attached in other ways. By way of example, the radioactive iodine may be conjugated directly to the fibrin by standard iodination reactions. In this fashion, the radioactive iodine or other radioactive element can be rapidly attached to the 30 patient's own proteins for use in autologous tissue glue.

It is also now appreciated that in addition to radiotherapy applications, these particles applied by tissue glue may be used to deliver a variety of other locally useful therapeutic agents. It is possible to 35 adhere nucleic acids onto these particles as disclosed in WO-A-9305815 and US Application Serial No. 08/211,041. It

is now also appreciated that in addition to genes, it is possible to adhere anti-sense oligonucleotides.

It is now known that gliomas involve a defect in a gene termed the p53 gene and that this defect can be 5 corrected by gene therapy, however there is no known way to deliver the therapeutic genes to the glioma cells (abnormal astrocytes). It is now disclosed that therapeutic genes for the treatment of brain tumours may be adhered to the surface of the particles and the complex then included in 10 a liquid component of the tissue glue. The glue is then applied at the time of surgery to the excision surface.

Astrocytes are phagocytic cells and have been demonstrated to avidly take up these particles into their interior, while neurons are far less phagocytic. By using 15 smaller particles and a looser matrix, the particles may be allowed to migrate slowly out of the matrix into the nearby or surrounding brain and to there be ingested by the actively phagocytic astrocytes. This may be further promoted by the use of targeting proteins or antibodies 20 which adhere to the surface of astrocytes generally or which may be targeted to markers expressed in excess amounts by cancerous astrocytes. These targeting proteins may be adhered to the particle surface by chemical conjugation by the periodate method, or by a variety of 25 other adhesion or conjugation methods well known to those skilled in the art.

It is further appreciated that nucleic acids may simply be incorporated into these glues by mixture without using these particles as carriers. Where particles are 30 used as carriers, a variety of types of particles is suitable, including cyanoacrylates, liposomes, albumin or other protein-based materials, starburst dextran dendrimers, starches, pectins, polylysine or other polymers.

35 Further, it has now been appreciated that viruses of sizes similar to the particles can also be immobilised in tissue glues. Thus, the therapeutic genes delivered by the

glue can be carried in retroviral vectors such as those described in WO-A-9317118 and US Application Serial No. 08/295,737, and also PCT/GB95/00663. The admixture of retroviral and other viral vectors into one component of a 5 tissue glue or settable matrix has a wide variety of applications where selected local gene therapy is desired. The viruses gain access to cells either by slow release from a loose matrix or by release associated with biodegradation of the gel matrix.

10 Alternatively, a loose gel may be used to immobilise cells infected with retroviral or other viral vectors or 'producer' cell lines containing all the genetic material needed to produce viral particles and a vector molecule for encapsidation therein. The cells are held in place by the 15 matrix, but the viral particles pass through the loose gel for the purpose of transfection or gene therapy. These immobilised cells can be used for local delivery of viral vectors or for delivery of vectors into the bloodstream for action at a distant site. Genetically-modified cells 20 trapped in a tissue glue can also be used as sources of therapeutic proteins which will then diffuse out of the gel after production in the modified implanted cells as with various growth factors, hormones, neurotransmitter modulating enzymes, antibodies, or cytokines.

25 In addition to the use of these particles for radiotherapy and for the delivery of genes, they may be used as transducers for the application of hyperthermy treatments. After placement of a ferrite particle containing gel, the patient may be exposed to oscillating 30 electromagnetic fields tuned to the particle type of particle used. Thus the particles can be caused to become hot and so provide a controllable heat therapy either separate from or in conjunction with their radiotherapeutic effect.

35 In addition to the potential for carriage of macromolecules, emission of radiation and transduction for heating, these particles can also be used as a means of

delivering cation therapy, as disclosed in WO-A-9211846 and US Application Serial No. 08/087,781 (see also above). In this system, various non-physiological cations are incorporated into the crystal matrix of the ferrite core.

5 The particles are then delivered in a tissue glue. Subsequently, as the glue breaks down or as the particles slowly leach out and are ingested by various cells, the cations are released through intracellular metabolism of the iron oxide core. Delivery of cations can be used for 10 the treatment of viral illness and also for cancer chemotherapy.

This antibiotic effect may also be exploited in a variety of hard coatings into which these particles may be incorporated. Where various cations offer anti-bacterial 15 effects, these may be used in coatings on e.g. various implants.

Additionally, the radiotherapeutic tissue glue can be augmented by the inclusion of synergistically acting diffusible drugs, either loosely incorporated in the gel 20 for free diffusion or introduced in semi-soluble or insoluble form in order to achieve slow release, or weakly adhered to the dextran or other polymer coating of particles. Such particles serve to temporarily immobilize and control the distribution of such drugs. Radiotherapy 25 can interfere with wound healing in some situations. It will therefore often be advantageous to counter the anti-wound healing effects of radiation by the inclusion of various growth factors in the gel as disclosed in WO-A-9420133 and WO-A-9209301. Further, it may be possible to 30 assist the anti-cancer effect of the radiation by inclusion of a variety of chemotherapeutic radio-sensitizer drugs or actual chemotherapeutic agents in the gel along with the radioactive source.

In addition to the various gels and glue carriers 35 mentioned above, it should be appreciated that the radiotherapeutic particles, particularly the EDTA-insoluble particles, can be dissolved in aqueous-based plastic

polymers which can then be caused to polymerize in the same fashion as described above for the tissue glues. The additional feature of a plastic is that it would allow for casting of a sealable shaped radiation carrier prior to 5 surgery or during surgery.

Yet another means of administration of the radiotherapeutic particles is in liquid form in association with specialised catheter systems which may or may not be further associated with endoscopic equipment. This could 10 be for a temporary application of radiotherapy. For example, in the case of the need to treat a localised lesion in a bronchus of the lung, the therapist would endoscopically introduce a very thin catheter with a much larger diameter balloon tip. At the time of introduction 15 the catheter would be completely collapsed by withdrawal of air and subsequent turning of an external sealing valve. Once the tip was positioned correctly, the radiotherapeutic liquid would be pumped into the catheter. Where the catheter is very thin, there will be only a very low dose 20 of radiation to surrounding normal tissue, however, a large amount of the agent would accumulate in the balloon tip and administer large amounts of radiation at that site (see figure 1). The volume of the catheter system and of the balloon tip can be precisely known so that only enough 25 radiotherapeutic agent to fill the balloon tip is pumped in. Then an immiscible liquid (e.g. paraffin oil) is pumped into the catheter as a chaser so that all of the radioactivity will be in the balloon tip and only cold chaser oil will be in the thin feeder catheter where it 30 traverses normal tissues. The catheter is fashioned of a plastics or other non-wettable material on which water beads readily and hence the oil is efficacious at substantially sweeping all the radioactive aqueous material distally towards the balloon.

35 In some situations, it will be desirable simply to introduce the liquid form of the brachytherapy agent (e.g. with palladium-103) into the tissue around the site of

tumor excision. These particles are preferentially cleared into and concentrated in lymph nodes. Similarly, an early stage in the spread of cancer away from its initial site is along the lymphatics where it is initially trapped in lymph nodes. The brachytherapy agent may be selectively concentrated in local lymph nodes and provides an additional selectively beneficial effect in preventing and treating any early spread of tumour cells. This is particularly important immediately after a surgical resection at which time numerous individual tumour cells are spilled by the surgeon in the process of physically mobilising and removing bulk tumour. These free floating tumour cells in the excision site are often cleared to lymph nodes where they can proliferate and to cause recurrence.

A solution of the particles may be aerosolized for spray application to a surface in the body in a system in which the spray forms part of a tissue glue which sets upon contact. Similarly, an aerosol route can be used with the liquid agent without glue for diffuse application in the bronchi or via the GI tract. An aerosol spray of the particle-carrying liquid can also be used to apply a thin layer of the particles in an even fashion to a sheet of implantable material. That sheet may then be sealed with a thin additional plastic layer. The inclusion of the elements in the nanoparticles will assure that radioactive elements will not diffuse through the pores of the plastic.

For applications such as cation therapy where containment is less of a concern, the tissue glue may be applied by spray-on application. An antibiotic fluid may be incorporated in the vehicle against any airborne contamination. In the spray-on methods, the fluid vehicle will either be so prepared as to polymerize in air, or two separate sprays may be used, first a carrier for the fibrin portion followed by the calcium and particle component. These applications may be from a pressurised can or from a simple standard nebulizer.

In order to apply the therapeutic tissue glue in applications where a layer must be applied to a surface, several specialized devices for this purpose may be used and are herein disclosed. Instead of two needles ending in 5 a point, the exits from the two application syringes are so fashioned that at their termini they widen into a flat applicator. The two channels are laid one over the other and attached to each other so that both deliver a sheet rather than a stream of glue components (see figure 2) and 10 these two sheets mix on exit, resulting in a sheet of controlled depth on the tissue surface. Each applicator kit can be supplied with several of these applicators so they may be readily replaced if they become clogged through 15 premature mixing of the two components. These sets of applicators may be provided in a series of widths including, e.g. 5, 10 or 20 mm, which may be selected based on the size and shape of the surface to be coated.

Further, in order to control the depth of the layer of the material, the applicator may be provided with paired 20 wheels. The wheels may either have latex rims or small feet so they do not produce furrows in the layer of the glue. The applicator may also be automated or semi-automated so that as the surgeon rolls the applicator along the surface the device measures the rate of 25 progression from the wheel turning and then automatically drives the two syringes to apply the layer of glue. Alternatively, as the surgeon presses the syringe, the advance of the plunger may mechanically cause the wheels to turn so that the device advances over the tissue surface at 30 the appropriate rate.

In addition to painting a layer of this therapeutic tissue glue onto the brain surface or onto the surface of any body tissue possibly invaded by cancer cells, it is also possible to inject a column or deposit of the glue in 35 a fashion similar to the catheter arrays used for brachytherapy, but in which a column of tissue glue incorporating radioactive nuclides in particles is

incorporated. Such administration can be monitored by concurrent imaging techniques which take advantage of the inherent imagability of the these particles (due to the density and magnetism of the iron core) by ultrasound, 5 magnetic resonance imaging, or X-ray based techniques, or the gel can be supplemented by an additive contrast agent.

Similarly, injection techniques can be used to inject settable, ferrite or other particle-containing gel into the centre of the tumour mass for purposes of brachytherapy, 10 either with or without the inclusion of chemical or biological agents capable of causing either increased radiation sensitivity or capable of acting as chemotherapeutic agents in their own right, to achieve a multi-modal attack on the cancer cells. Administration in 15 this manner can also be achieved by injecting the glue with radioopaque material but without the ferrite/particle solution, using two barrels/needles from a three-part syringe system. Then, once the position, shape, and setting of the glue are confirmed, the third barrel/needle 20 can be used to inject the particle solution into the centre of the matrix/glue material which will hold the material within its interstices. The needle is then very slowly withdrawn along with the injection of additional glue, to seal the needle tract.

25 Any such one, two, or three-barrel system for administration of glue-based radiotherapy products may be equipped with a release mechanism for detaching a plastic or silastic inside layer at the tip of the needle. This is provided in case the column of glue becomes adherent to the 30 tip of the needle and allows the operator to choose to leave the plastic behind in the needle tract to avoid pulling out the column of glue as the needle is withdrawn. Alternatively, this problem can be avoided with a more standard glue application system as long as a 'chaser' of 35 cold glue is use to follow the injection of radioactive glue.

In many situations, it will be desirable to inject the radiotherapeutic glue in an array which distributes the therapeutic material through the mass at a variety of locations. An example of this occurs when a stereotactic 5 system is used to allow a neurosurgeon to place a needle or catheter into the middle of a brain tumour by passing through a burr hole in the skull. Because of the need to traverse brain tissue, it is undesirable to make numerous 10 needle passes in order to reach multiple sites in the tumor. It has now been appreciated that a novel type of administration device would solve this problem as well as similar problems arising in other body regions where bulk 15 tumor is to be treated. The system (see figure 3) involves an outer sheath of a hard material such as steel, titanium or plastics which carries a plurality of internal flexible needle pairs which are prestressed to spread outwards from the tip of the sheath. The needle pairs are withdrawn 20 within the sheath while the tip of the sheath is advanced into the tumor. The internal set of needle pairs is then advanced, upon which their tips emerge from the sheath and spread in various directions and so puncture the tumor from inside towards the outside in various directions. Once at 25 their full extent, injection is commenced as the needles are withdrawn back into the sheath. The internal apparatus can then be rotated, e.g. 45° and then advanced a second time. After being withdrawn into the sheath again, the sheath may then be advanced further into the tumor upon 30 which the internal needle are again advanced.

The following Example gives the steps to be taken in 35 an illustrative synthetic method for particles to be included in a matrix.

Example

Add 1.5 ml of 33% NH₃ to 4.5 ml of hot dH₂O (to make up 7.5% NH₄OH) and leave standing in a capped universal 35 tube in the water bath and bring to 60°C.

Dissolve 1.25 grams of Dextran (MW 10,000) in 2.0 ml of ddH₂O then dissolve 225 mg FeCl₃.6H₂O in the dextran

solution. Other macromolecules such as proteins, fibrin, collagen, starch, polylysine, or derivatized dextrans may also be used for the coating. Alternatively, a trivalent lanthanide or Group IIIB chloride may be substituted for 5 10-50% of the $FeCl_3$. A variety of unstable isotopes of various transition, lanthanide and actinide elements can be introduced at this step as metal chlorides dissolved in water or in an acidic solution of e.g. 0.1M HCl. The amount of trivalent iron may be reduced where trivalent 10 cations are added.

Dissolve 100 mg $FeCl_2 \cdot 4H_2O$ in the Fe_3 /dextran solution then place the mixture in a 60°C water bath for two minutes. Some divalent cations may be added in place of Fe at this step. Some metal chlorides such as, e.g. palladium 15 chloride will require an extended period of time up to e.g. one to two days in concentrated HCl in order to become fully dissolved prior to mixing with the other constituents. When trivalent lanthanides are used, the crystal structure may be modified by the use of copper or 20 magnesium as the divalent cation instead of the $FeCl_2$, or other stable combination of cations such as $FeCl_2$ with $ZnCl_2$, may be used to help accommodate Group IIIB elements such as 25 the yttrium⁹⁰ isotope. Further, the reaction mixture may be allowed to stand at room temperature or be cooled as low as 0-4°C prior to proceeding depending upon the desired size distribution of the resultant particles where cooler reaction temperatures tend to produce smaller particles.

Gradually add 6 ml of hot 7.5% NH_3 solution (60°C). The NH_3 solution may also be added at lower temperatures, 30 e.g. 0-4°C or room temperature. Equivalence of temperature and mixing to assure uniform concentration as well as more gradual and dispersive addition of the NH_3 solution will help reduce the range of particle sizes. The product is left to stand in the 60°C water bath for fifteen minutes 35 for Fe/Fe particles, but the incubation may be extended up to four hours when lanthanides or Group IIIB elements in substantial amount are used in place of $FeCl_3$.

The reaction product (dextran-coated ferrites) is spun at 1,000 g for 10 minutes and any precipitate is discarded. This process is repeated to complete three spins and the supernatant then applied to PD-10 columns equilibrated with 5 0.1M Na Acetate buffer pH 6.8 with 5mM EDTA.

The black eluted fraction is diluted 1:3 with EDTA/Acetate buffer then concentrated to 1/10 of the initial volume with Amicon Centriprep-100 ultrafilters. The retentate is then diluted 1:10 with EDTA/Acetate buffer 10 then concentrated to a volume of 1.5 ml with the C-100 ultrafilters.

At this point the preparation may be stored or further concentrated. If it is to be used with a tissue glue, it can be mixed with one component of the fibrinogen, fibrin, 15 collagen, acrylic, gelatin, resorcinol or other type of tissue glue, matrix, or polymer precursor prior to application and mixing of the glue to set on the tissue surface.

When it is desired to attach an additional ligand such 20 as for instance an antibody, lectin, or other agent which promotes adherence to the glue matrix, the following steps as well as other methods well known to those expert in the art of conjugation to dextran may be used.

Add 0.30 ml of 20 mM NaIO₄ to the dextran ferrite 25 solution (approx. 1.5 ml) while stirring then gently tumble or shake for 60 minutes at room temperature in the dark.

At the end of the 60 minute periodate incubation, the reaction is terminated by applying the reaction mixture to the PD-10 columns equilibrated with 20mM borate buffer (pH 30 8.5).

An active site blocking solution is prepared using 100 mM MnCl₂/CaCl₂ for WGA binding reactions and appropriate blocking agent for any other targeting protein to be conjugated to the particle.

35 Dissolve 10 mg of the protein (e.g. cell targeting protein or antibody) in 500 μ l of 20mM NaBorate buffer pH 8.5 at room temperature. The protein solution can be

diluted to 12 ml with borate buffer, then concentrated with Centriprep-10 concentrators to remove DTT, glycerol, NaN₃, and other undesirable storage additives.

5 Add 10 μ l of the blocking solution to the protein/borate solution then mix 2.0 ml of oxidized magnetite dextran with 500 μ l of the protein/borate solution. Pipette 20 μ l blocking solution into the 2.5 ml protein-dextran-magnetite mixture and mix well, then incubate for 6-18 hours at room temperature in a gentle 10 tumbling or shaking device.

15 After the incubation add 100 l of 0.5M glycine to the reaction mixture and incubate an additional 2 hours. Then add 250 μ l of 0.25M NaBH₄ to the magnetite-dextran-protein solution and allow to stand for 60 minutes, shaking periodically to release H₂ gas. At the end of the 20 incubation, pass the reaction mixture through PD-10 columns equilibrated with 20mM HEPES buffer, pH 7.4. Dilute the eluant 1:5 with HEPES buffer then concentrate with Centriprep-100 ultrafilters.

25 An affinity purification step is optional and detail is given for use with a WGA(lectin) targeting protein by example. Apply final retentate to affinity columns (20 mM HEPES), wash with HEPES then carry out specific elution with 1M NAcGlu in HEPES buffer pH 7.4. Pass the specific eluant through PD-10 columns equilibrated with HEPES to remove NAcGlu, Mn and Ca.

30 The desalted output is then diluted to a volume of 24 ml with HEPES buffer and concentrated with Centriprep-100 concentrators. The final retentate form is sterilized by spinning at 500 g for one hour in 0.22 μ m centrifugal microfilters.

Brief Description of the Drawings

35 Figure 1 shows a balloon-tipped catheter system, for temporary introduction of liquid brachytherapy agent, including a catheter 1, collapsed balloon tip 2, stopcock 3, an adapter 4, radiotherapeutic liquid 5 and an immiscible 'chaser' fluid 6. Fig. 5A shows the parts of

the system; the four stages of its use are: B) the assembled system with air evacuated from the catheter and balloon, both being collapsed, the stopcock valve maintaining a seal, C) a column of radiotherapeutic fluid 5 being pumped into the catheter, D) the fluid reaching and starting to fill the balloon tip, E) the balloon tip fully filled with radiotherapeutic liquid and non-radioactive immiscible chaser fluid filling the catheter up to the balloon entry point. Optionally, a second tube may be used 10 to fill an internal balloon, or the first tube used to send down a leading column of fluid to dilate an internal balloon with the purpose of creating a thin shell of radioactive fluid against the inner surface of the outer balloon.

15 Figure 2 shows a lead-shielded double-syringe device for applying a thin sheet of radiotherapeutic tissue glue. The syringes include barrels, one indicated at 7, a wheel 8 placed between the terminal portions of the dispenser plates to maintain a uniform distance from the tissue 20 surface, an optional wheel 9 with penetrating feet, an optional wheel 10 with a thin silastic outer rim, and two dispenser plates 11 seen in lateral view, one behind the other. Fig. 2F is a lateral view of the system without the spacing wheel; Fig. 2G is a lateral view of the system with 25 one of the optional wheels in place, and Fig. 2H is an anterior view of the assembled double-syringe system showing the appearance of one of the various widths and shapes of disposable dispenser plates which may be affixed to the syringe system.

30 Figure 3 shows a device for distributing therapeutic adhesive within a tumor mass, including a sheath 12, a plunger shaft 13, a plunger/manifold cover 14, needles 15 (at 15b, viewed from above with four double-barrelled needles extended), double-barrelled syringe 16, connecting 35 tubing 17 for carrying glue components to a manifold 18 dividing flow of glue components into four sets and then pairing up the sets of double-barrelled needles, one pair

of needles shown at 19 emerging from manifold cover to enter the plunger shaft, and, shown at 20, a fully-extended set of double-barrelled needles spreading out from sheath tip to penetrate tumor in various directions. Fig. 3J 5 shows the plunger lifted to withdraw needles back into the sheath. Fig. 3K shows the plunger advanced to force the four double-barrelled needle sets out into the tumor in various directions, and Fig. 3L shows the syringe manifold system which allows distribution of the two component glue 10 into the double-barrelled needles after they are in place and while they are being withdrawn.

Table 1

Relevant Stable Nuclides $^{ 6}_{\Lambda} C$ 12(98.9%), 13(1.1%) $^{ 8}_{\Lambda} O$ 16(99.76%), 17(0.04%), 18(0.2%) $^{ 25}_{\Lambda} Mn$ 55(100%) $^{ 26}_{\Lambda} Fe$ 54(6%), 56(92%), 57(2%), 58(0.3%) $^{ 27}_{\Lambda} Co$ 59(100%) $^{ 28}_{\Lambda} Ni$ 58(68%), 60(26%), 61(1%), 62(4%) $^{ 38}_{\Lambda} Sr$ 84(.6%), 86(10%), 87(7%), 88(82%) $^{ 39}_{\Lambda} Y$ 89(100%) $^{ 40}_{\Lambda} Zr$ 90(51%), 91 (11%), 92(17%), 94(18%), 96(3%) $^{ 44}_{\Lambda} Ru$ 96(5%), 98 (2%), 99(12%), 100(12%), 101(17%), 102(32%), 104(18%) $^{ 45}_{\Lambda} Rh$ 103(100%) $^{ 46}_{\Lambda} Pd$ 102(1%), 105(22%), 106(27%), 108(26%), 110(11%) $^{ 47}_{\Lambda} Ag$ 107(52%), 109 (48%)

Table 2

Pd	n,γ	n,p	α,2n
102	103Pd (17d,EC)	102Rh (2.9y,EC)	104Cd (58m,EC)
105	106Pd (stable)	105Rh (35h,β-)	107Cd (6h,EC/β+)
106	107Pd (10 ⁶ y,β-)	106Rh (29s,β-)	108Cd (stable)
108	109Pd (13h,β-)	108Rh (17s,β-)	110Cd (stable)
110	110Pd (stable)	110Rh (3s,β-)	112Cd (stable)

34
Table 3

<i>Cyclotron</i>	<i>Reactor</i>
<i>(p,n)</i>	<i>(n,γ)</i>
$^{56}\text{Fe} \rightarrow ^{56}\text{Co}$ (77d, β^+)	$^{56}\text{Fe} \rightarrow ^{57}\text{Fe}$ (stable)
$^{16}\text{O} \rightarrow ^{16}\text{F}$ (10 ⁻²⁰ s, p)	$^{16}\text{O} \rightarrow ^{17}\text{O}$ (stable)
$^{12}\text{C} \rightarrow ^{12}\text{N}$ (11ms, β^+, α)	$^{12}\text{C} \rightarrow ^{13}\text{C}$ (stable)
$^{103}\text{Rh} \rightarrow ^{103}\text{Pd}$	$^{102}\text{Pd} \rightarrow ^{103}\text{Pd}$ (17.5d, EC)
	$^{89}\text{Y} \rightarrow ^{90}\text{Y}$ (64h, β^-)
<i>(d,n)</i>	<i>(n,p)</i>
$^{56}\text{Fe} \rightarrow ^{57}\text{Co}$ (271d, EC)	$^{56}\text{Fe} \rightarrow ^{56}\text{Mn}$ (2.6h, β^-)
$^{16}\text{O} \rightarrow ^{17}\text{F}$ (64s, β^+)	$^{16}\text{O} \rightarrow ^{16}\text{N}$ (7s, β^-, α)
$^{12}\text{C} \rightarrow ^{13}\text{N}$ (9min, β^+)	$^{12}\text{C} \rightarrow ^{12}\text{B}$ (.02s, β^-, α)
<i>(α,pn)</i>	$^{90}\text{Zr} \rightarrow ^{90}\text{Y}$ (64h, β^-)
$^{56}\text{Fe} \rightarrow ^{58}\text{Co}$ (70d, β^+)	
$^{16}\text{O} \rightarrow ^{18}\text{F}$ (109min, β^+)	
$^{12}\text{C} \rightarrow ^{14}\text{N}$ (stable)	
$^{88}\text{Sr} \rightarrow ^{90}\text{Y}$ (64h, β^-)	
<i>(α,2n)</i>	
$^{56}\text{Fe} \rightarrow ^{58}\text{Ni}$ (stable)	
$^{16}\text{O} \rightarrow ^{18}\text{Ne}$ (1.7s, β^+)	
$^{12}\text{C} \rightarrow ^{14}\text{O}$ (70s, β^+)	
$^{101}\text{Ru} \rightarrow ^{103}\text{Pd}$	


CLAIMS

1. A composition comprising a tissue glue and, retained in the glue, a therapeutic agent whose therapeutic effect is mediated locally, on degradation of the glue.
- 5 2. A composition according to claim 1, which additionally comprises a material that accelerates degradation of the glue.
3. A composition according to claim 2, wherein the glue is proteinaceous and said material is proteolytic.
- 10 4. A composition according to claim 1, which additionally comprises a material that inhibits degradation of the glue.
5. A composition according to any preceding claim, wherein said agent is radiotherapeutic (or convertible to a radiotherapeutic agent).
- 15 6. A composition according to claim 5, wherein said agent is in the form of a chelate holding a radioactive atom.
7. A composition according to claim 5 or claim 6, wherein said agent is a ferrite.
- 20 8. A composition according to any of claims 5 to 7, which additionally comprises a radiation sensitiser capable of leaching out and augmenting the local radiotherapeutic effect.
9. A composition according to any of claims 5 to 8, which additionally comprises a growth factor or other substance that mitigates the anti-wound-healing effect of radiation.
- 25 10. A composition according to any of claims 5 to 9, wherein said agent comprises a zinc-substituted yttrium ferrite, or a ⁵⁶Fe-enriched ferrite.
11. A composition according to any of claims 5 to 10, wherein said agent comprises ¹⁰³Pd or ⁹⁰Y.
- 30 12. A composition according to any preceding claim, wherein said agent is adapted to be ingested by astrocytes.
13. A composition according to any preceding claim, wherein said agent is a viral vector.
- 35 14. A composition according to any preceding claim, wherein said agent comprises a drug and a particulate carrier.

15. Use of the components of a composition according to any preceding claim, for the manufacture of a medicament for use in treating a tumour or other condition for which the therapeutic effect is desired.
- 5 16. A composition comprising a tissue glue and, retained in said glue, a radiotherapeutic agent as defined in any of claims 5 to 14, or a precursor thereof.
- 10 17. A method for the radiotherapy of a tumour, which comprises applying to said tumour an effective amount of a radiotherapeutic agent as defined in any of claims 5 to 14, and a tissue glue.

1/3

FIGURE 1



2/3





Figure 2

3 / 3

FIGURE 2



INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/GB 95/01330

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/00 A61K9/20 A61K47/32 A61K47/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 22312 (J.WADSTRÖM) 23 December 1992 see claims 1,3,11,14,16,24 ---	1,14
X	WO,A,93 05067 (BAXTER INTERNATIONAL INC.,U.S.A.) 18 March 1993 see claims 52-54,60-66 ---	1,14
X	DATABASE WPI Week 9306, Derwent Publications Ltd., London, GB; AN 93-049554 (06) see abstract & JP,A,05 000 970 (SUMITOMO CEMENT CO.) 8 January 1993 --- -/-	1-4,14

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

*** Special categories of cited documents :**

- ‘A’ document defining the general state of the art which is not considered to be of particular relevance
- ‘E’ earlier document but published on or after the international filing date
- ‘L’ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- ‘O’ document referring to an oral disclosure, use, exhibition or other means
- ‘P’ document published prior to the international filing date but later than the priority date claimed

- ‘T’ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- ‘X’ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- ‘Y’ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- ‘&’ document member of the same patent family

1

Date of the actual completion of the international search

23 October 1995

Date of mailing of the international search report

27.10.1995

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Scarpioni, U

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/01330

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 534 178 (OCTAPHARMA AG) 31 March 1993 see claims ---	1-4
P,X	WO,A,94 20133 (THE AMERICAN NATIONAL RED CROSS,U.S.A.) 15 September 1994 cited in the application see claims 1,3-6 -----	1,14

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Search Application No

PCT/GB 95/01330

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9222312	23-12-92	AU-A- 2149192 EP-A- 0590015 JP-T- 6508363 NO-A- 934592	12-01-93 06-04-94 22-09-94 14-02-94
WO-A-9305067	18-03-93	AU-A- 2577992 CA-A- 2117058 EP-A- 0602173 JP-T- 7501517	05-04-93 18-03-93 22-06-94 16-02-95
JP-A-05000970	08-01-93	NONE	
EP-A-0534178	31-03-93	WO-A- 9305822 AU-B- 648198 AU-A- 2528892 CZ-A- 9202942 HU-A- 67051 JP-A- 5194263 ZA-A- 9207360	01-04-93 14-04-94 01-04-93 16-02-94 30-01-95 03-08-93 03-05-93
WO-A-9420133	15-09-94	AU-B- 6364894	26-09-94